Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the latest clinical study results of its novel VEGF-targeting monoclonal antibody (R&D code: 9MW0211) in neovascular (wet) age-related macular degeneration (nAMD) will be presented as a poster presentation, at the 2026 World Ophthalmology Congress (WOC) in Prague, Czech Republic, June 26-29, 2026.

Poster Presentation

Title: Efficacy and Safety of 9MW0211 for nAMD: 52-week results from the seamless phase 2/3 trial

Abstract No.: PP-RET-090

Principal Investigator: Prof. Zhang Ming, West China Hospital of Sichuan University

Session Date and Time: 6/26/2026 3:30PM-4:30PM (local time)